Recurrent and fatal akinetic crisis in genetic‐mitochondrial parkinsonisms
暂无分享,去创建一个
[1] A. Schapira,et al. Mitochondria and Quality Control Defects in a Mouse Model of Gaucher Disease—Links to Parkinson’s Disease , 2013, Cell metabolism.
[2] John-Paul Taylor,et al. Cohort study of prevalence and phenomenology of tremor in dementia with Lewy bodies , 2013, Journal of Neurology.
[3] A. Consiglio,et al. Interplay of LRRK2 with chaperone-mediated autophagy , 2013, Nature Neuroscience.
[4] Chunyan Wang,et al. Leucine‐rich repeat kinase 2 disturbs mitochondrial dynamics via Dynamin‐like protein , 2012, Journal of neurochemistry.
[5] M. Onofrj,et al. Cohort study on somatoform disorders in Parkinson disease and dementia with Lewy bodies , 2010, Neurology.
[6] B. Margetić,et al. Neuroleptic malignant syndrome and its controversies , 2010, Pharmacoepidemiology and drug safety.
[7] A. Singleton,et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. , 2009, Brain : a journal of neurology.
[8] M. Zeviani,et al. Two novel POLG1 mutations in a patient with progressive external ophthalmoplegia, levodopa-responsive pseudo-orthostatic tremor and parkinsonism , 2008, Neuromuscular Disorders.
[9] M. Onofrj,et al. Akinetic crisis, acute akinesia, neuroleptic malignant‐like syndrome, Parkinsonism–hyperpyrexia syndrome, and malignant syndrome are the same entity and are often independent of treatment withdrawal , 2005, Movement disorders : official journal of the Movement Disorder Society.
[10] C. Klein,et al. Early-onset parkinsonism associated with PINK1 mutations: Frequency, genotypes, and phenotypes , 2005, Neurology.
[11] M. Onofrj,et al. Acute akinesia in Parkinson disease , 2005, Neurology.
[12] R. Nussbaum,et al. Hereditary Early-Onset Parkinson's Disease Caused by Mutations in PINK1 , 2004, Science.
[13] Janel O. Johnson,et al. α-Synuclein Locus Triplication Causes Parkinson's Disease , 2003, Science.
[14] I. Kanazawa,et al. A collaborative study on the malignant syndrome in Parkinson's disease and related disorders. , 2003, Parkinsonism & related disorders.
[15] S. Tsuji,et al. A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2–q13.1 , 2002, Annals of neurology.
[16] M Zappia,et al. Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease , 2001, Movement disorders : official journal of the Movement Disorder Society.
[17] A. Terashi,et al. Susceptibility to neuroleptic malignant syndrome in Parkinson’s disease , 1999, Neurology.
[18] H. Möller,et al. Inhibition of complex I by neuroleptics in normal human brain cortex parallels the extrapyramidal toxicity of neuroleptics , 1997, Molecular and Cellular Biochemistry.
[19] J. Kelly,et al. Neuroleptic medications inhibit complex I of the electron transport chain , 1993, Annals of neurology.
[20] J. Hughes,et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. , 1992, Journal of neurology, neurosurgery, and psychiatry.